Glaxosmithkline Phar
Ticker > Company >

Glaxosmithkline Phar share price

Glaxosmithkline Pharmaceuticals Ltd.

NSE: GLAXO BSE: 500660 SECTOR: Pharmaceuticals & Drugs  1.36 L   433   57

2835.40
+62.00 (2.24%)
BSE: 04 Sep 04:01 PM

Price Summary

Today's High

₹ 2880

Today's Low

₹ 2756

52 Week High

₹ 3515.95

52 Week Low

₹ 1924.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 48033.39 Cr.

Enterprise Value

₹ 46632.5 Cr.

No. of Shares

16.94 Cr.

P/E

50.98

P/B

22.15

Face Value

₹ 10

Div. Yield

1.9 %

Book Value (TTM)

₹  128.02

CASH

₹ 1400.89 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

75 %

EPS (TTM)

₹  55.61

Sales Growth

9.28%

ROE

48.92 %

ROCE

66.95%

Profit Growth

57.19 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Glaxosmithkline Pharmaceuticals Ltd.

Piriton Betnovate Augmentin Ceftum Calpol Phexin Betnesol Eltroxin Zinetac Neosporin Cetzine Havrix Varilrix Rotarix Hiberix Cervarix Crocin Eno IODEX Horlicks OSTOCALCIUM Otrivin ActiGrow Choco

Index Presence

The company is present in 31Indices.

NFT150MOM50

Nifty Midcap150 Momentum 50
60184.1
  -592.200000000004 (-0.974392978842087%)

NFT500MOM50

Nifty500 Momentum 50
50979.65
  -307.299999999996 (-0.599177763544134%)

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
47749.7
  -235 (-0.489739437779124%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
44253.05
  -55.0499999999956 (-0.124243648452527%)

NFT500MOQ50

Nifty500 Multicap Momentum Quality 50 index
40981.9
  -22.6999999999971 (-0.05535964257668%)

NFT500MULTI

Nifty500 Multifactor MQVLv 50
30800.55
  35.4500000000007 (0.115227969354881%)

NMID150Q50

NIFTY Midcap150 Quality 50
24237.75
  -45.5999999999985 (-0.187782987108442%)

NIFTY500

Nifty 500
22819.65
  -45 (-0.196810360097355%)

NIFTYMIDCAP150

Nifty Midcap 150
21157.95
  -134.299999999999 (-0.630745928682963%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19624.2
  -127.549999999999 (-0.645765565076506%)

NIFTY500QUAL50

Nifty500 Quality 50 Index
19020.5
  -2.20000000000073 (-0.0115651300814368%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17532.35
  -77.3500000000022 (-0.439246551616446%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
16010.45
  -51.8999999999996 (-0.323115857891276%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15898.6
  -53.1000000000004 (-0.332879881141201%)

NFT500EQUAL

Nifty 500 Equal Weight
14181.8
  -85.9500000000007 (-0.602407527465798%)

NIFTYTOTALMCAP

Nifty Total Market index
12846.45
  -27.5999999999985 (-0.214384750719454%)

MIDCAP

S&P Bse Mid Cap
45504.35
  -276.340000000004 (-0.603616939805851%)

BSE HC

S&P Bse Healthcare
44245.59
  -3.93000000000029 (-0.00888145227337933%)

BSE500

S&P Bse 500
35845.46
  -59.6900000000023 (-0.166243561160451%)

BSE500QTY50

BSE 500 Quality 50
21483.04
  24.9200000000019 (0.116133193401846%)

MID150

S&P Bse 150 MidCap
15838.52
  -104.26 (-0.653963737817376%)

200EQW

BSE 200 Equal Weight
12815.98
  -66.0200000000004 (-0.512498059307565%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
11907.97
  -73.9099999999999 (-0.616848107308698%)

BSE200

S&P Bse 200
11210.78
  -11.9299999999985 (-0.106302310226303%)

BSE1000

Bse 1000
10682.33
  -20.8400000000001 (-0.194708670421939%)

LMI250

S&P Bse 250 LargeMidCap
10653.49
  -13.1399999999994 (-0.123187923458479%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SPBSQIP

S&P Bse Quality
1833.3
  0.889999999999873 (0.0485699161213882%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year9.28%
3 Year4.99%
5 Year2.92%

Profit Growth

1 Year57.19%
3 Year-18.38%
5 Year52.88%

ROE%

1 Year48.92%
3 Year36.39%
5 Year28.88%

ROCE %

1 Year66.95%
3 Year50.15%
5 Year43%

Debt/Equity

0

Price to Cash Flow

37.53

Interest Cover Ratio

950.9588

CFO/PAT (5 Yr. Avg.)

1.35712487700278

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 75.00 0.00
Mar 2025 75.00 0.00
Dec 2024 75.00 0.00
Sep 2024 75.00 0.00
Jun 2024 75.00 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 34.6362930722251% for the Past 3 years.
  • Company has been maintaining healthy ROE of 36.3897333333333% over the past 3 years.
  • Company has been maintaining healthy ROCE of 50.1516333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 950.9588.
  • The Company has been maintaining an effective average operating margins of 23.1622926901252% in the last 5 years.
  • Company’s PEG ratio is 0.891569563597358.
  • The company has an efficient Cash Conversion Cycle of -109.3726 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.35712487700278.
  • The company has a high promoter holding of 75%.

 Limitations

  • The company has shown a poor revenue growth of 4.98885093852781% for the Past 3 years.
  • The company is trading at a high PE of 50.98.
  • The company is trading at a high EV/EBITDA of 34.7721.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 811 1000.05 946.36 966.08 804.83
Total Expenditure 581.58 681.1 656.18 635.34 554.08
Operating Profit 229.42 318.95 290.18 330.74 250.75
Other Income 35.85 32.19 35.06 39.46 43.76
Interest 0.37 0.27 0.09 0.58 0.42
Depreciation 16.41 16.86 18.8 14.72 15.52
Exceptional Items 0 4.69 0 0 0
Profit Before Tax 248.49 338.7 306.35 354.9 278.57
Tax 66.84 90.01 77.77 94.76 73.87
Profit After Tax 181.65 248.69 228.58 260.14 204.7
Adjusted EPS (Rs) 10.72 14.68 13.49 15.36 12.08

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 2920.48 3217.51 3216.34 3407.25 3723.49
Total Expenditure 2322.7 2461.68 2416.92 2506.6 2554.2
Operating Profit 597.77 755.83 799.43 900.65 1169.29
Other Income 110.19 76.22 101.51 123.48 142.56
Interest 3.53 1.99 1.81 1.8 1.31
Depreciation 78.6 68.19 65.77 69.68 66.79
Exceptional Items -172.6 11.58 -0.97 -143.62 4.69
Profit Before Tax 453.23 773.44 832.39 809.04 1248.44
Tax 166.54 396.87 227.69 224.35 329.39
Net Profit 357.57 1690.53 607.75 584.69 919.05
Adjusted EPS (Rs.) 16.92 22.23 35.7 34.51 54.25

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 169.41 169.41 169.41 169.41 169.41
Total Reserves 1327.71 2508.21 1583.59 1614.69 1779.82
Borrowings 0 0 0 0 0
Other N/C liabilities 178.87 157.84 124.49 106.82 110.25
Current liabilities 1319.42 1674.35 1317.03 1510.94 1900.81
Total Liabilities 2995.41 4509.81 3194.52 3401.85 3960.29
Assets
Net Block 385.56 329.44 328.9 320.36 282.87
Capital WIP 13.21 30.5 20.31 13.93 14.32
Intangible WIP 0 0 0 0 0
Investments 24.49 24.49 24.49 24.49 24.49
Loans & Advances 392.45 448.04 351.98 275.12 253.87
Other N/C Assets 188.48 6.74 2.12 2.11 1.19
Current Assets 1991.21 3670.6 2466.72 2765.84 3383.55
Total Assets 2995.41 4509.81 3194.52 3401.85 3960.29
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 722.33 2470.04 837.49 952.65 1243.74
Adjustment -25.25 -1636.93 -40.86 -46.14 -68.98
Changes in Assets & Liabilities 63.03 134.89 -39.02 64.55 186.18
Tax Paid -146.91 -112.15 -262.86 -252.67 -80.93
Operating Cash Flow 594.87 819.79 487.94 578.94 1280.03
Investing Cash Flow 407.57 -419.66 805.19 14.97 -36.53
Financing Cash Flow -695.56 -524.24 -1544.18 -561.5 -769.42
Net Cash Flow 306.87 -124.11 -251.05 32.41 474.07

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 75.00 75.00 75.00 75.00 75.00
burroughs wellcome intern... 3.97 3.97 3.97 3.97 3.97
eskaylab limited 6.94 6.94 6.94 6.94 6.94
glaxo group limited 35.99 35.99 35.99 35.99 35.99
glaxosmithkline pte limit... 28.10 28.10 28.10 28.10 28.10
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 25.00 25.00 25.00 25.00 25.00
investor education and pr... - - 0.63 0.63 0.63
lici asm non par 1.61 - 1.27 - 1.15
sbi quant fund - - - - 1.19
life insurance corporatio... - 1.32 - 1.19 -
sbi nifty midcap 150 inde... - - - 1.27 -
investor education and pr... 0.58 0.63 - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q3FY25
Concall Q3FY24
Concall Q2FY24
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY20
Presentation FY2024

Company News

Glaxosmithkline Pharmaceuticals forays into India’s Oncology market 25 Aug, 2:12 PM GlaxoSmithKline Pharmaceuticals informs about press release 25 Aug, 12:18 PM GlaxoSmithKline Pharmaceuticals informs about clarification 4 Aug, 12:25 PM Glaxosmithkline Phar - Quaterly Results 1 Aug, 12:35 PM Glaxosmithkline Phar - Quaterly Results 1 Aug, 12:35 PM Glaxosmithkline Phar - Quaterly Results 1 Aug, 12:35 PM GlaxoSmithKline Pharmaceuticals informs about analyst meet 28 Jul, 4:20 PM GlaxoSmithKline Pharmaceuticals informs about analyst meet 28 Jul, 3:50 PM GlaxoSmithKline Pharmaceuticals informs about analyst meet 20 Jun, 4:44 PM GlaxoSmithKline Pharmaceuticals informs about transcript of analyst meetings 15 May, 5:09 PM GlaxoSmithKline Pharmaceuticals informs about newspaper advertisements 15 May, 5:07 PM GlaxoSmithKline Pharmaceuticals informs about secretarial compliance report 15 May, 5:03 PM GlaxoSmithKline Pharmaceuticals submits analyst meet intimation 13 May, 5:34 PM GlaxoSmithKline Pharmaceuticals informs about outcome of board meeting 13 May, 5:07 PM Glaxosmithkline Phar - Quaterly Results 13 May, 4:04 PM Glaxosmithkline Phar - Quaterly Results 13 May, 4:04 PM Glaxosmithkline Phar - Quaterly Results 13 May, 4:04 PM GlaxoSmithKline Pharmaceuticals informs about increase in volumes 25 Apr, 1:57 PM GlaxoSmithKline Pharmaceuticals informs about disclosure 9 Apr, 2:23 PM GlaxoSmithKline Pharmaceuticals informs about newspaper advertisements 31 Mar, 3:15 PM GlaxoSmithKline Pharmaceuticals informs about postal ballot notice 28 Mar, 5:16 PM GlaxoSmithKline Pharmaceuticals informs about disclosure 28 Feb, 12:05 PM Glaxosmithkline Pharmaceuticals informs about press release 17 Feb, 5:25 PM Glaxosmithkline Pharmaceuticals informs about analyst meet 15 Feb, 2:10 PM Glaxosmithkline Phar - Quaterly Results 14 Feb, 3:27 PM Glaxosmithkline Phar - Quaterly Results 14 Feb, 3:27 PM Glaxosmithkline Phar - Quaterly Results 14 Feb, 3:27 PM Glaxosmithkline Pharmaceuticals informs about analyst meet 11 Feb, 2:22 PM Glaxosmithkline Pharmaceuticals informs about disclosure 11 Feb, 12:27 PM Glaxosmithkline Pharmaceuticals informs about board meeting 15 Jan, 2:35 PM GlaxoSmithKline Pharmaceutical informs about change in directorate 6 Jan, 1:08 PM Glaxosmithkline Pharmaceuticals informs about receipt of order 27 Nov, 11:47 AM Glaxosmithkline Phar - Quaterly Results 29 Oct, 3:44 PM Glaxosmithkline Phar - Quaterly Results 29 Oct, 3:44 PM Glaxosmithkline Phar - Quaterly Results 29 Oct, 3:44 PM Glaxosmithkline Pharmaceuticals informs about loss of share certificate 1 Oct, 4:52 PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificate 24 Sep, 2:35 PM GlaxoSmithKline Pharmaceuticals informs about disclosure 26 Aug, 5:08 PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates 14 Aug, 2:34 PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates 13 Aug, 12:04 PM Glaxosmithkline Pharmaceuticals informs about analyst meet 8 Aug, 3:26 PM GlaxoSmithKline Pharmaceuticals informs about outcome of schedule of analyst meet 6 Aug, 12:19 PM Glaxosmithkline Phar - Quaterly Results 2 Aug, 3:35 PM Glaxosmithkline Phar - Quaterly Results 2 Aug, 3:35 PM Glaxosmithkline Phar - Quaterly Results 2 Aug, 3:35 PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates 30 Jul, 12:11 PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate Share Certificates 22 Jul, 5:03 PM Glaxosmithkline Pharmaceuticals board to consider unaudited financial results 17 Jul, 4:02 PM Glaxosmithkline Pharmaceuticals informs about compliance certificate 4 Jul, 1:22 PM GlaxoSmithKline Pharmaceuticals informs about closure of trading window 27 Jun, 2:18 PM

Glaxosmithkline Phar Stock Price Analysis and Quick Research Report. Is Glaxosmithkline Phar an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Glaxosmithkline Phar. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Glaxosmithkline Phar has a PE ratio of 51.27983816588 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Glaxosmithkline Phar has ROA of 24.9669% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Glaxosmithkline Phar has a Current ratio of 1.7801.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Glaxosmithkline Phar has a ROE of 48.9219%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Glaxosmithkline Phar has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Glaxosmithkline Phar has reported revenue growth of 9.2814% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Glaxosmithkline Phar for the current financial year is 31.402983589901%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Glaxosmithkline Phar is Rs 54 and the yield is 1.8997%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Glaxosmithkline Phar is Rs 55.6125. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Glaxosmithkline Phar in Ticker for free. Also, one can get the intrinsic value of Glaxosmithkline Phar by using Valuation Calculators, which are available with a Finology ONE subscription. 

Glaxosmithkline Phar FAQs

Q1. What is Glaxosmithkline Phar share price today?
Ans: The current share price of Glaxosmithkline Phar is Rs 2851.8.

Q2. What is the market capitalisation of Glaxosmithkline Phar?
Ans: Glaxosmithkline Phar has a market capitalisation of Rs 48311.21277612 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Glaxosmithkline Phar?
Ans: The PE ratio of Glaxosmithkline Phar is 51.27983816588 and the P/B ratio of Glaxosmithkline Phar is 22.2754934422503, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Glaxosmithkline Phar share?
Ans: The 52-week high share price of Glaxosmithkline Phar is Rs 3515.7, and the 52-week low share price of Glaxosmithkline Phar is Rs 1921.

Q5. Does Glaxosmithkline Phar pay dividends?
Ans: Currently, Glaxosmithkline Phar pays dividends. Dividend yield of Glaxosmithkline Phar is around 1.8997%.

Q6. What are the face value and book value of Glaxosmithkline Phar shares?
Ans: The face value of Glaxosmithkline Phar shares is Rs 10, while the book value per share of Glaxosmithkline Phar is around Rs 128.0241. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Glaxosmithkline Phar?
Ans: Glaxosmithkline Phar has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Glaxosmithkline Phar?
Ans: The ROE of Glaxosmithkline Phar is 48.9219% and ROCE of Glaxosmithkline Phar is 66.9511%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Glaxosmithkline Phar a good buy for the long term?
Ans: The Glaxosmithkline Phar long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Glaxosmithkline Phar undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Glaxosmithkline Phar appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Glaxosmithkline Phar’s financials?
Ans: You can review Glaxosmithkline Phar’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Glaxosmithkline Phar

Glaxosmithkline Pharmaceuticals Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Glaxosmithkline Pharmaceuticals Ltd. is a leading pharmaceutical company in India, providing a wide range of healthcare products to its customers.  We will provide a comprehensive analysis of Glaxosmithkline Pharmaceuticals Ltd.'s stock performance and key financial indicators for long-term stock investors looking for stock analysis.

Glaxosmithkline Pharmaceuticals Ltd. Share Price

Glaxosmithkline Pharmaceuticals Ltd.'s share price has been consistently increasing over the years due to the company's strong financial performance and growth prospects. The company has a stable business model and a diverse range of clients, which provides investors with a sense of security and stability. Investors can use Ticker pre-built screening tools to track Glaxosmithkline Pharmaceuticals Ltd.'s share price and compare it with other companies in the industry.

Glaxosmithkline Pharmaceuticals Ltd. Balance Sheet

Glaxosmithkline Pharmaceuticals Ltd.'s balance sheet is a reflection of the company's financial health and stability. The company has a strong balance sheet with a healthy debt-to-equity ratio and a high current ratio. Ticker premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools provide investors with a comprehensive understanding of the company's financial position and help them make informed investment decisions.

Glaxosmithkline Pharmaceuticals Ltd. Annual Report

Glaxosmithkline Pharmaceuticals Ltd.'s annual reports provide detailed information about the company's operations, financial performance, and future prospects. Investors can download the annual reports from Ticker and analyze the company's performance over the years. The annual report also includes information about the company's management team, corporate governance practices, and sustainability initiatives.

Glaxosmithkline Pharmaceuticals Ltd. Dividend

Glaxosmithkline Pharmaceuticals Ltd. has a consistent track record of paying dividends to its shareholders. The company has a dividend payout ratio of over 30%, which indicates that it is committed to sharing its profits with its shareholders. Investors can track Glaxosmithkline Pharmaceuticals Ltd.'s dividend history using Ticker pre-built screening tools and compare it with other companies in the industry.

Glaxosmithkline Pharmaceuticals Ltd. Quarterly Result

Glaxosmithkline Pharmaceuticals Ltd.'s quarterly results provide an insight into the company's performance over a shorter period. The company's revenue and profits can be affected by various factors such as changes in government policies, fluctuations in commodity prices, and global economic conditions. Ticker premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools provide investors with a comprehensive understanding of the company's financial position and help them make informed investment decisions.

Glaxosmithkline Pharmaceuticals Ltd. Stock Price

Glaxosmithkline Pharmaceuticals Ltd.'s stock price is influenced by various factors such as the company's financial performance, market conditions, and investor sentiment. Investors can track Glaxosmithkline Pharmaceuticals Ltd.'s stock price using our pre-built screening tools and compare it with other companies in the industry. 

Glaxosmithkline Pharmaceuticals Ltd. Price Chart

Glaxosmithkline Pharmaceuticals Ltd.'s price chart provides a visual representation of the company's stock performance over a period of time. Investors can use our pre-built screening tools to analyze Glaxosmithkline Pharmaceuticals Ltd.'s price chart and compare it with other companies in the industry. 

Glaxosmithkline Pharmaceuticals Ltd. News

Glaxosmithkline Pharmaceuticals Ltd.'s news section provides investors with the latest updates about the company's operations, financial performance, and future prospects. Investors can stay informed about the company's developments by regularly checking the news section on Ticker.

Glaxosmithkline Pharmaceuticals Ltd. Concall Transcripts

Glaxosmithkline Pharmaceuticals Ltd.'s concall transcripts provide investors with an opportunity to listen to the management team's views on the company's performance and future prospects. Investors can download the concall transcripts from Ticker and gain valuable insights into the company's operations.

Glaxosmithkline Pharmaceuticals Ltd. Investor Presentations

Glaxosmithkline Pharmaceuticals Ltd.'s investor presentations provide a comprehensive overview of the company's operations, financial performance, and future prospects. Investors can download the investor presentations from Ticker and gain a deeper understanding of the company's business model and growth prospects.

Glaxosmithkline Pharmaceuticals Ltd. Promoters

Glaxosmithkline Pharmaceuticals Ltd.'s promoters include some of the leading business conglomerates in India. The company has a strong backing from its promoters, which provides investors with a sense of security and stability.

Glaxosmithkline Pharmaceuticals Ltd. Shareholders

Glaxosmithkline Pharmaceuticals Ltd.'s shareholders include retail investors, institutional investors, and the company's promoters. The company has a diverse shareholder base, which indicates that it is a popular investment choice among investors.

Glaxosmithkline Pharmaceuticals Ltd. ROCE

Return on Capital Employed (ROCE) is a pivotal financial metric that indicates a company's efficiency in generating profits from its capital investments. At our stock analysis page, you can access the ROCE data for Glaxosmithkline Pharmaceuticals Ltd. in the financials table or ratio section. This information helps investors evaluate the company's ability to utilize its capital effectively and compare its performance to industry benchmarks.

Glaxosmithkline Pharmaceuticals Ltd. EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a significant metric that reflects the operational profitability of a company. On our stock analysis page, you can find EBITDA data for Glaxosmithkline Pharmaceuticals Ltd. in the financials table or ratio section. Analyzing the EBITDA provides insights into the company's core business profitability and its capacity to generate cash flow.

Glaxosmithkline Pharmaceuticals Ltd. DPS

Dividends Per Share (DPS) is a financial metric that indicates the amount of dividends distributed to each outstanding share. You can find DPS data for Glaxosmithkline Pharmaceuticals Ltd. on our stock analysis page, available in the financials table or ratio section. Understanding the DPS can assist investors in evaluating the company's dividend distribution policy and its potential as an income-generating investment.

Glaxosmithkline Pharmaceuticals Ltd. EPS

Earnings Per Share (EPS) is a crucial metric that measures a company's profitability on a per-share basis. Investors can find the EPS data for Glaxosmithkline Pharmaceuticals Ltd. on our stock analysis page in the financials table or ratio section. Analyzing the EPS provides valuable insights into the company's earnings performance and growth potential, aiding investors in making informed investment decisions. 

GlaxoSmithKline Pharmaceuticals Reserves

Analyzing GlaxoSmithKline Pharmaceuticals' financial health through its balance sheet reveals a mixed trend in its total reserves. From March 2020's ?1,670.63 Cr, there was a decline to ?1,327.71 Cr in March 2021. Interestingly, a significant increase was observed in March 2022 with reserves at ?2,508.21 Cr, followed by a decrease to ?1,614.69 Cr by March 2024. This fluctuation indicates the company's dynamic approach to managing its surplus funds over the years.

GlaxoSmithKline Pharmaceuticals Debt

The balance sheet showcases that GlaxoSmithKline Pharmaceuticals has maintained minimal borrowing since March 2020, with figures falling to zero from 2021 onwards. This reflects the company's strong position in terms of debt management and its capacity to sustain operations without significant external borrowing.

GlaxoSmithKline Pharmaceuticals Assets

GlaxoSmithKline Pharmaceuticals' assets have seen substantial growth, specifically in the current assets category, escalating from ?1,756.67 Cr in March 2020 to ?2,765.84 Cr by March 2024. However, the net block has undergone depreciation over the years, with a decrease from ?756.59 Cr to ?320.36 Cr in the same period, signifying a possible reinvestment into more liquid and operational assets.

GlaxoSmithKline Pharmaceuticals Balance Sheet Overview

The data provided is an analysis for the Standalone Balance Sheet of the company, indicating an overall increment in total liabilities and assets from ?3,022.68 Cr in March 2020 to ?3,401.85 Cr by March 2024. Such financial insights are imperative for investors screening stocks and considering market trends in pharmaceutical sectors or evaluating potential IPOs.

Read More
X